First-line maintenance therapy of adult patients with BCG-naïve high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) - SunRISe-3 - AB 85/23 of AUO
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Aktuelle Urologie - 54(2023), 4 vom: 18. Aug., Seite 272-273 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Erstlinien-Erhaltungstherapie bei erwachsenen Patienten mit BCG-naivem Hochrisiko – nicht muskelinvasivem Blasenkarzinom |
|---|
| Links: |
|---|
| Themen: |
Adjuvants, Immunologic |
|---|
| Anmerkungen: |
Date Completed 07.08.2023 Date Revised 07.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-2059-0186 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360409253 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360409253 | ||
| 003 | DE-627 | ||
| 005 | 20231226082942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1055/a-2059-0186 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360409253 | ||
| 035 | |a (NLM)37541235 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 245 | 1 | 0 | |a First-line maintenance therapy of adult patients with BCG-naïve high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) - SunRISe-3 - AB 85/23 of AUO |
| 246 | 3 | 3 | |a Erstlinien-Erhaltungstherapie bei erwachsenen Patienten mit BCG-naivem Hochrisiko – nicht muskelinvasivem Blasenkarzinom |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.08.2023 | ||
| 500 | |a Date Revised 07.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a BCG Vaccine |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Aktuelle Urologie |d 1981 |g 54(2023), 4 vom: 18. Aug., Seite 272-273 |w (DE-627)NLM121152979 |x 1438-8820 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2023 |g number:4 |g day:18 |g month:08 |g pages:272-273 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-2059-0186 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2023 |e 4 |b 18 |c 08 |h 272-273 | ||